MediciNova granted Notice of Allowance for MN-001 patent by USPTO

MediciNova (MNOV) has received a Notice of Allowance from the USPTO for a pending patent application for MN-001 – Tipelukast – to cover “Method to Decrease Triglyceride Synthesis in a Liver of a Subject.” The allowed claims cover a method for decreasing triglyceride synthesis in the liver by administering MN-001 or its metabolite or pharmaceutically acceptable salt. This method is beneficial for subjects diagnosed with insulin resistance, pre-diabetes, or diabetes. Once issued, this patent is expected to expire no earlier than May 26, 2042. The Notice of Allowance is a critical step towards the issuance of the patent.